Vasculitis & polymyalgia rheumatica
Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis
Authors' conclusion
The GTI is capable of capturing GC toxicity in AAV and identifies patients at increased risk for GC side effects.
Study context
- Population
- Patients with confirmed antibodies-associated vasculitides (AAV)
- Participants
- 138 patients
- Outcome
- GC toxicity assessed by the GTI (GTI-AIS and GTI-CWS) and its relationship with GC exposure, toxicity and disease activity
- Follow-up
- T1 baseline, t2 6 months later
Methodological detailsmonocentric
- Monocentric
Main finding
As reported in the abstract
- Median cumulative glucocorticoids (GC) dose (mg)
- 9014.0
- GC exposure and toxicity significantly correlated
- p<0.001
- GTI-AIS significantly higher in active disease vs remission
- p<0.001
- GTI-CWS significantly higher in long-standing disease
- p=0.013
- GTI-CWS significantly higher with high cumulative GC doses
- p=0.003
Observational data: associations, not effects.
Safety
Most frequent adverse events
- Skin atrophy, osteoporosis and myopathy
Original publication
Prospective study of complications and sequelae of glucocorticoid therapy in ANCA-associated vasculitis. RMD Open. Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →